Loading…
MARKETS
TOOLS
LEARN
Equiscale · Syntellia LLC
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics. The company offers animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences; OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural characteristics for challenging targets; OmnidAb, an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold; and OmniDeep, a suite of in silico, an artificial intelligence (AI) and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. It has an agreement with mAbsolve Ltd. for its Fc-silencing platform technology to incorporate the STR technology into antibodies that have been generated using OmniAb's antibody discovery platform. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $19M | $-47M | $-65M | $-37M | -24.3% | -29.3% | 4.4% |
| 2024 | $26M | $-51M | $-62M | $-42M | -21.6% | -22.8% | 22.5% |
| 2023 | $34M | $-50M | $-51M | $1M | -16.1% | -42.2% | 126.6% |
| 2022 | $59M | $-8M | $-22M | $-21M | -6.5% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 59.08 | 34.16 | 26.39 | 18.67 |
| Operating Revenue | - | 59.08 | 34.16 | 26.39 | 18.67 |
| Cost Of Revenue | - | - | - | 0 | 0.30 |
| Gross Profit | - | - | - | 26.39 | 18.36 |
| Operating Expense | - | 85.72 | 103.58 | 100.89 | 87.33 |
| Research And Development | - | 48.36 | 56.52 | 55.11 | 47.75 |
| Selling General And Administration | - | 24.90 | 33.31 | 30.74 | 29.22 |
| Total Expenses | - | 85.72 | 103.58 | 100.89 | 87.64 |
| Operating Income | - | -26.65 | -69.42 | -74.50 | -68.97 |
| Total Operating Income As Reported | - | -26.65 | -69.42 | -74.50 | -68.97 |
| EBITDA | - | -8.40 | -49.92 | -50.92 | -47.22 |
| Normalized EBITDA | - | -8.40 | -49.92 | -50.92 | -47.22 |
| EBIT | - | -26.65 | -69.42 | -74.50 | -68.97 |
| Interest Income | - | 0.59 | 5.06 | 3.11 | 2.66 |
| Interest Expense | 0.01 | 0 | - | - | - |
| Net Interest Income | - | 0.59 | 5.06 | 3.11 | 2.66 |
| Other Non Operating Income Expenses | 1.27 | - | 0 | -0.02 | 0.02 |
| Other Income Expense | 1.27 | - | 0 | -0.02 | 0.02 |
| Interest Income Non Operating | - | 0.59 | 5.06 | 3.11 | 2.66 |
| Interest Expense Non Operating | 0.01 | 0 | - | - | - |
| Net Non Operating Interest Income Expense | - | 0.59 | 5.06 | 3.11 | 2.66 |
| Pretax Income | - | -26.06 | -64.36 | -71.41 | -66.29 |
| Tax Provision | - | -3.73 | -13.74 | -9.38 | -1.52 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -22.33 | -50.62 | -62.03 | -64.78 |
| Net Income From Continuing And Discontinued Operation | - | -22.33 | -50.62 | -62.03 | -64.78 |
| Net Income From Continuing Operation Net Minority Interest | - | -22.33 | -50.62 | -62.03 | -64.78 |
| Net Income | - | -22.33 | -50.62 | -62.03 | -64.78 |
| Net Income Common Stockholders | - | -22.33 | -50.62 | -62.03 | -64.78 |
| Net Income Including Noncontrolling Interests | - | -22.33 | -50.62 | -62.03 | -64.78 |
| Normalized Income | - | -22.33 | -50.62 | -62.03 | -64.78 |
| Diluted NI Availto Com Stockholders | - | -22.33 | -50.62 | -62.03 | -64.78 |
| Basic Average Shares | - | 85.32 | 99.68 | 102.36 | 113.64 |
| Diluted Average Shares | - | 85.32 | 99.68 | 102.36 | 113.64 |
| Reconciled Depreciation | - | 18.25 | 19.50 | 23.58 | 21.75 |
| Reconciled Cost Of Revenue | - | - | - | 0 | 0.30 |
| Depreciation Amortization Depletion Income Statement | - | 13.05 | 13.55 | 17.41 | 12.91 |
| Depreciation And Amortization In Income Statement | - | 13.05 | 13.55 | 17.41 | 12.91 |
| General And Administrative Expense | - | 24.90 | 33.31 | 30.74 | 29.22 |
| Other Gand A | - | 24.90 | 33.31 | 30.74 | 29.22 |
| Other Operating Expenses | - | -0.59 | 0.19 | -2.37 | -2.55 |
| Amortization | - | 13.05 | 13.55 | 17.41 | 12.91 |
| Amortization Of Intangibles Income Statement | - | 13.05 | 13.55 | 17.41 | 12.91 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| OmniAb, Inc.this co. | OABI | $386M | -5.95 | 1.44 | -24.3% | -8.06 |
| Community Health Systems, Inc. | CYH | $393M | 0.77 | -0.28 | -36.5% | 5.53 |
| TruBridge, Inc. | TBRG | $391M | 89.74 | 2.20 | 2.4% | 12.54 |
| Compass Therapeutics, Inc. | CMPX | $384M | -5.77 | 1.95 | -33.8% | -5.08 |
| Benitec Biopharma Inc. | BNTC | $380M | -10.01 |
| - |
| - |
| - |
| - |
| 3.90 |
| -39.0% |
| -6.83 |
| Viemed Healthcare, Inc. | VMD | $377M | 25.26 | 2.67 | 10.6% | 7.36 |
| CapsoVision, Inc. | CV | $377M | -14.88 | 28.41 | -190.9% | -14.73 |
| Vanda Pharmaceuticals Inc. | VNDA | $376M | - | 1.15 | -67.4% | - |
| Lexeo Therapeutics, Inc. | LXEO | $375M | -3.75 | 1.52 | -40.5% | -3.28 |
| Peer Median | - | -3.75 | 2.07 | -37.7% | -3.28 | |
Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen — at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in “Average from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
Historically, May has averaged the highest return (+18.2%); Apr the lowest (-12.8%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -1.6%Neutral MonthJan 2026: -1.62% | -5.5%Negative MonthFeb 2026: -5.49% | -8.7%Negative MonthMar 2026: -8.72% | -11.5%Negative MonthApr 2026: -11.46% | +94.2%Positive MonthMay 2026: +94.24% | -8.9%Negative MonthJun 2026: -8.89% | -19.5%Negative MonthJul 2026: -19.51% | +111.6%*Positive MonthAug 2026: +111.62% | — | — | — | — |
| 2025 | -9.0%Negative MonthJan 2025: -9.04% | +8.1%Positive MonthFeb 2025: +8.07% | -31.0%Negative MonthMar 2025: -31.03% | -29.2%Negative MonthApr 2025: -29.17% | -25.3%Negative MonthMay 2025: -25.29% | +37.0%Positive MonthJun 2025: +37.01% | +9.8%Positive MonthJul 2025: +9.77% | -16.2%Negative MonthAug 2025: -16.23% | +0.0%Neutral MonthSep 2025: +0.00% | -3.1%Negative MonthOct 2025: -3.13% | +16.8%Positive MonthNov 2025: +16.77% | +2.2%Positive MonthDec 2025: +2.21% |
| 2024 | -6.0%Negative MonthJan 2024: -6.00% | +0.7%Neutral MonthFeb 2024: +0.69% | -7.2%Negative MonthMar 2024: -7.19% | -18.1%Negative MonthApr 2024: -18.08% | -2.3%Negative MonthMay 2024: -2.25% | -13.6%Negative MonthJun 2024: -13.59% | +27.7%Positive MonthJul 2024: +27.73% | -12.5%Negative MonthAug 2024: -12.53% | +1.0%Neutral MonthSep 2024: +0.95% | -3.3%Negative MonthOct 2024: -3.31% | -4.4%Negative MonthNov 2024: -4.40% | -9.5%Negative MonthDec 2024: -9.46% |
| 2023 | +15.0%Positive MonthJan 2023: +15.00% | +0.7%Neutral MonthFeb 2023: +0.72% | -11.8%Negative MonthMar 2023: -11.75% | -5.4%Negative MonthApr 2023: -5.43% | +24.1%Positive MonthMay 2023: +24.14% | +16.4%Positive MonthJun 2023: +16.44% | +9.3%Positive MonthJul 2023: +9.34% | +5.5%Positive MonthAug 2023: +5.45% | -10.5%Negative MonthSep 2023: -10.52% | -12.3%Negative MonthOct 2023: -12.33% | -3.5%Negative MonthNov 2023: -3.52% | +40.5%Positive MonthDec 2023: +40.55% |
| 2022 | -0.8%Neutral MonthJan 2022: -0.80% | +0.6%Neutral MonthFeb 2022: +0.60% | +1.0%Neutral MonthMar 2022: +1.00% | +0.0%Neutral MonthApr 2022: +0.00% | +0.2%Neutral MonthMay 2022: +0.20% | -0.2%Neutral MonthJun 2022: -0.20% | +0.4%Neutral MonthJul 2022: +0.40% | +0.5%Neutral MonthAug 2022: +0.49% | +0.3%Neutral MonthSep 2022: +0.34% | -33.9%Negative MonthOct 2022: -33.86% | -47.6%Negative MonthNov 2022: -47.56% | +1.7%Neutral MonthDec 2022: +1.69% |
| 2021 | — | — | — | — | — | — | — | — | — | +2.4%Positive MonthOct 2021: +2.36% | +0.1%Neutral MonthNov 2021: +0.10% | +0.0%Neutral MonthDec 2021: +0.00% |
| Avg±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation — the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position — all Januaries together, all Februaries together, and so on — to show whether a given month has leaned positive or negative historically. ‘Simple’ counts each month as +1 or −1. ‘Weighted’ gives larger moves more influence: +2 above +10%, −2 below −10%. With only 6 years of history for this asset, each month’s score reflects a small number of observations — read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
